1 Annual Report 2024 Chairman’s Letter We are delighted to present INOVIQ’s Annual Report for the financial year ended 30 June 2024. OUTLOOK AND PLANS INOVIQ is a leading biotechnology company pioneering next-generation diagnostics and therapeutics to enhance patient outcomes in cancer and other diseases. Over the next 12-months, our priorities include: › expanding our exosome isolation tools, › partnering our lead SubB2M diagnostics, › accelerating the development of our exosome diagnostics and therapeutics pipeline, and › growing revenues from EXO-NET product sales and partnering. INOVIQ is strongly positioned with disruptive technology, a multiproduct pipeline, commercial partners validating its technology, and an experienced leadership team to execute on strategy. The Company is well-funded to leverage our existing technologies while exploring strategic M&A opportunities. I thank shareholders for their ongoing support and look forward to keeping you informed on our progress. Mr David Williams Chairman Dear shareholder, We are delighted to present INOVIQ’s Annual Report for the financial year ended 30 June 2024. STRATEGIC DIAGNOSTICS FOCUS INOVIQ has been transformed from a single-asset diagnostics company developing a lung cancer test to a biotechnology company developing next-generation diagnostics and therapeutics for cancer. The Company is leveraging its core technologies to build a portfolio of revenue-generating research tools and high-value diagnostics and therapeutics including: › EXO-NET and NEURO-NET research tools for isolating panexosomes or specific-exosomes from the brain › Exosome test for screening ovarian cancer in asymptomatic women › Tests for monitoring breast or ovarian cancer treatment response and recurrence ACHIEVEMENTS The Company partnered with Promega to distribute its exosome research tools globally and enable other researchers to develop exosome diagnostics using our exosome platform. INOVIQ progressed its SubB2M diagnostics towards commercialisation for monitoring breast and ovarian cancers. It also expanded our exosome capabilities to develop third-generation immunotherapies for solid tumours. These initiatives will de-risk INOVIQ’s business including through early EXO-NET revenue. STRATEGIC THERAPEUTICS FOCUS While continuing to expand our exosome diagnostic capabilities, the Company is giving more focus to cancer therapeutics. This includes an exosome therapeutic to target and kill breast cancer. FINANCIAL PERFORMANCE INOVIQ ended FY24 with a cash balance of $9.2m, following a placement. The Share Purchase Plan component of the capital raise completed post 30 June 2024, delivering a further $2.4m in July 2024. Funds are being primarily employed in advancing our SubB2M and EXO-NET programs. The Company reported a net loss from operating activities (after income tax) for the year of $6.6 million. Chairman’s Letter
RkJQdWJsaXNoZXIy MjE2NDg3